X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.
Lead Product(s): ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-2173
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2022
Details:
ATI-1428 and ATI-1645 are 4th generation, class II capsid assembly modulators (CAMs), both with a novel and unique ultra-potent mechanism of action design that may provide for a more targeted, productive antiviral response by the immune system.
Lead Product(s): ATI-1428
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1428
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.
Lead Product(s): Clevudine Monophosphate Prodrug,Tenofovir,Vebicorvir
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-2173
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.
Lead Product(s): Clevudine Monophosphate Prp,Tenofovir Disoproxil Fumarate
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-2173
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
Under the agreement, Antios will purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) which is being developed for the treatment of HBV.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: IRBM
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 15, 2021
Details:
The proceeds from this financing will be used to advance the clinical development of ATI-2173, Antios’ lead Phase 2b clinical candidate. ATI-2173 is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development.
Lead Product(s): ATI-2173,Tenofovir Disoproxil Fumarate,AB-729
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-2173
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GordonMD Global Investments
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 03, 2021
Details:
ATI-2173 has, to date, demonstrated a generally well-tolerated safety profile, leveraging a unique ASPIN mechanism in clinical development to empower combination therapy.
Lead Product(s): ATI-2173,Vebicorvir
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-2173
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Assembly Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 19, 2021
Details:
The multi-center, double-blinded, placebo-controlled, multiple-dose cohort will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of the combination of ATI-2173, AB-729 and Viread.
Lead Product(s): AB-729,ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area: Infections and Infectious Diseases Product Name: GalNAc-RNAi
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Arbutus Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 30, 2021
Details:
The double-blind randomized controlled trial plans to enroll 30 patients and will assess the safety and efficacy of 25mg and 50mg doses of ATI-2173 in combination with tenofovir (TDF) compared with TDF plus ATI-placebo (control) in chronic HBV-infected subjects.
Lead Product(s): ATI-2173
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-2173
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2021
Details:
The proceeds from this financing will support the ongoing Phase 2 clinical program which is evaluating the potential for the Company’s lead clinical candidate, ATI-2173, to be a backbone of a once-daily curative regimen for chronic hepatitis B.
Lead Product(s): ATI-2173
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-2173
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $96.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
